Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
$1.18
Est. revenue
$874M
Implied move
±8.6%
EPS beat rate
13%
Royalty Pharma plc is a leading player in the health care sector, focusing on acquiring and managing pharmaceutical royalties. With a market cap of $25 billion, the company plays a crucial role in funding the development of new therapies while benefiting from the sales of established drugs.
Last quarter
In the last quarter, Royalty Pharma reported a loss of $0.04 per share, which was below expectations. The revenue details were not disclosed, indicating potential challenges in meeting market forecasts.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
+5.28%
Avg 1-day reaction
+0.00%
Analysts are cautiously optimistic about Royalty Pharma's upcoming earnings, with expectations set for a modest profit and stable revenue. The consensus EPS is $1.18, suggesting a recovery in performance.
Bull case
If the company can exceed the EPS estimate, it may signal strong management of its royalty portfolio and potential for future growth, boosting investor confidence.
Bear case
Conversely, if earnings fall short of expectations again, it could raise concerns about the sustainability of its royalty revenue and impact stock performance negatively.
Key metrics to watch
EPS
$1.18Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$874MTotal revenue reflects the company's ability to generate sales from its royalty agreements and is vital for assessing growth.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $1.18?
A positive EPS surprise could indicate improved profitability and operational efficiency, which is crucial for investor sentiment.
Q2
What revenue figures will be reported, and how do they compare to the consensus of $874M?
Revenue performance is essential for understanding the company's growth trajectory and the health of its royalty agreements.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating the potential for a turnaround in earnings, given the company's focus on managing its royalty portfolio effectively.
Supporting evidence
The options market is pricing an 8.6% move, suggesting greater volatility than historical averages.
Insider selling activity could indicate a lack of confidence in short-term performance, contrasting with the optimistic consensus.
Key risk
If EPS comes in below $1.15, it could undermine the current positive sentiment and lead to a reevaluation of growth expectations.
Pre-commit to what would confirm each case.
The market is weighing the potential for recovery in earnings against the backdrop of previous losses, making this quarter critical for future expectations.
Bull confirmed if
An EPS of $1.20 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $1.15 would raise concerns about profitability and future growth prospects.
What the market is pricing for the move.
Implied Move
±8.6%
The options market is pricing in a significant move in either direction, indicating uncertainty among investors about the upcoming earnings report.
ATM IV
0.3%
30d HV
22.1%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$474,407.48
8,252 sh
1 insider
Net
$474,407.48
Net selling
Most Active Insiders· 2 open-market trades
$474,407.48
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
87.68%
of float
Insider
6.49%
of float
Holders
997
institutions
Top Holders· as of Jun 2026
Morgan Stanley
42,931,597 sh · $2.4B
9.64%
-1.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Royalty Pharma beats EPS expectations, history suggests the stock could see an average one-day move of +3.4%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in management's future guidance.
Miss
A miss on earnings could lead to a decline, with historical patterns suggesting an average drop of around -0.4%.
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $57.88
4,126 sh
$238,812.88
Oct 5, 2026 · @ $57.10
4,126 sh
$235,594.60
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Capital International Investors
35,273,770 sh · $2.0B
7.92%
0.8%
Blackrock Inc.
27,832,977 sh · $1.6B
6.25%
7.4%
FMR, LLC
24,513,814 sh · $1.4B
5.51%
-2.5%
State Street Corporation
12,338,229 sh · $700.3M
2.77%
12.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.